BMS 962476

Drug Profile

BMS 962476

Alternative Names: BMS-962476; PCSK9 Adnectin

Latest Information Update: 02 May 2016

Price : $50

At a glance

  • Originator Adnexus Therapeutics
  • Developer Adnexus Therapeutics; Bristol-Myers Squibb
  • Class Antihyperlipidaemics; Recombinant fusion proteins
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hypercholesterolaemia

Most Recent Events

  • 02 May 2016 No recent reports on development identified - Phase-I for Hypercholesterolaemia in USA (IV & SC)
  • 26 Feb 2013 Phase-I clinical trials in Hypercholesterolaemia in USA (SC & IV)
  • 26 Apr 2012 Preclinical trials in Hypercholesterolaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top